Related Experiment Video
Updated: May 2, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
10.7K
Apolipoprotein E receptor pathways in Alzheimer disease
Vanessa Schmidt1, Anne-Sophie Carlo, Thomas E Willnow
1Max-Delbrueck-Center for Molecular Medicine, Berlin, Germany.
Summary
Alzheimer disease (AD) involves amyloid-β (Aβ) peptides. Apolipoprotein E (apoE) and its receptors are crucial in Aβ clearance and neuroprotection, with defects leading to neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer disease (AD) is a prevalent neurodegenerative disorder.
- The amyloid cascade hypothesis posits neurotoxic amyloid-β (Aβ) oligomers cause AD pathology.
- Apolipoprotein E (apoE) is a major genetic risk factor for sporadic AD.
Purpose of the Study:
- To review the molecular interactions between apoE, its receptors, and neuronal function in AD.
- To elucidate the role of apoE pathways in neurodegeneration.
- To highlight the significance of apoE in the amyloid cascade.
Main Methods:
- Literature review focusing on molecular interactions.
- Analysis of the role of apoE and its receptors in Aβ clearance and aggregation.
- Examination of the link between apoE pathway defects and neurodegeneration.
Main Results:
- Apolipoprotein E (apoE) influences amyloid-β (Aβ) clearance and oligomerization.
- ApoE receptors mediate critical cellular and systemic effects of apoE.
- Dysfunctional apoE-receptor pathways contribute to neurodegeneration in Alzheimer disease.
Conclusions:
- ApoE and its receptors are central to maintaining neuronal viability and function.
- Defects in apoE-mediated pathways are implicated in the pathogenesis of Alzheimer disease.
- Understanding these molecular interactions is key for developing AD therapies.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:22Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
01:24Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28